北京市兰台律师事务所 关于 黑龙江珍宝岛药业股份有限公司 回购注销 2023 年限制性股票激励计划 部分限制性股票的 法律意见书 地址:北京市朝阳区曙光西里甲1号第三置业B座29层 电话: （8610）52287799 传真: （8610）58220039 邮编: 100028 网址：www.lantai.cn 二〇二五年四月 法律意见书 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 回购注销 2023 年限制性股票激励计划部分限制性股票的 法律意见书 兰台意字(2025) 第 1951 号 致:黑龙江珍宝岛药业股份有限公司 北京市兰台律师事务所(以下简称"兰台"或"本所")接受黑龙江珍宝岛 药业股份有限公司(以下简称"公司"或"珍宝岛")的委托,作为公司 2023 年限制性股票激励计划(以下简称"本次股权激励计划")的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会 〈以下简称"中国证监会"〉《上市公司股权激励管理办法》(以下简称"《管 理办法》")及其他有关法律、法规和规范性文件,及《 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 中国·北京 BEIJING CHINA 目 录 1、关于黑龙江珍宝岛药业股份有限公司募集资金年度存 放与实际使用情况的鉴证报告 1-2 2、黑龙江珍宝岛药业股份有限公司关于 2024 年度募集资 金存放与实际使用情况的专项报告 1-9 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 中审亚太审字（2025）005289 号 黑龙江珍宝岛药业股份有限公司全体股东： 我们接受委托，对后附的黑龙江珍宝岛药业股份有限公司（以下简称"珍宝 岛公司"）截至 2024 年 12 月 31 日止的《董事会关于公司募集资金年度存放与 实际使用情况的专项报告》进行了鉴证工作。 按照中国证监会发布的《上市公司监管指引第 2 ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,703,934,334.17, a decrease of 13.84% compared to 2023[20]. - The net profit attributable to shareholders for 2024 was CNY 438,216,195.63, down 7.30% from the previous year[20]. - The net profit after deducting non-recurring gains and losses increased significantly to CNY 402,967,474.16, compared to a loss of CNY 31,842,460.08 in 2023, marking a 1,365.50% increase[20]. - The net cash flow from operating activities improved to CNY 164,308,401.91, a 134.36% increase from the previous year[20]. - The total assets at the end of 2024 were CNY 12,712,631,463.50, reflecting a 1.98% increase from 2023[20]. - The basic earnings per share for 2024 was CNY 0.4662, a decrease of 7.35% compared to 2023[21]. - The weighted average return on equity decreased to 5.70%, down 0.76 percentage points from the previous year[21]. - The company achieved operating revenue of 2.704 billion yuan and a net profit attributable to shareholders of 438 million yuan for the reporting period[29]. - The company’s main business revenue for the reporting period was 2.677 billion RMB, a year-on-year decrease of 13.20%, while the main business cost was 1.186 billion RMB, a year-on-year decrease of 33.10%[112]. - The total cost for the current period is CNY 1,186,321,312.29, a decrease of 33.10% compared to CNY 1,773,283,468.40 in the same period last year[121]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares, totaling approximately 141.13 million yuan, which accounts for 32.21% of the net profit attributable to ordinary shareholders[4]. - The total share capital as of December 31, 2024, is 941,140,609 shares, with 940,859,283 shares eligible for the dividend distribution after accounting for treasury shares[4]. - The company does not plan to issue bonus shares or convert reserves into share capital in this profit distribution[4]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[6]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[5]. - There are no violations of decision-making procedures regarding external guarantees[5]. - The company has detailed various risks and countermeasures in the management discussion and analysis section of the report[6]. Audit and Compliance - The company has received a standard unqualified audit report from Zhongshun Yatai Accounting Firm[3]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[3]. - The company has not disclosed any significant changes in its operational address or registration during the reporting period[16]. Research and Development - The company is focusing on R&D in traditional Chinese medicine, particularly in cardiovascular, digestive, respiratory, and immune treatment areas, with ongoing clinical evaluations and quality standard improvements[57]. - The company has completed preclinical research for its 1.1 class innovative traditional Chinese medicine (TCM) drug, receiving clinical trial approval from the regulatory authority[151]. - The company has five formulation projects that have obtained production approval and three projects that have completed registration applications during the reporting period[152]. - The company has initiated phase I clinical trials for its innovative drug HZB1006, a second-generation FGFR inhibitor, which has shown promising progress[152]. - The company is actively collaborating with renowned universities and research institutions to enhance its TCM research capabilities, focusing on areas such as cardiovascular, respiratory, and oncology diseases[151]. - The company has established a comprehensive R&D incubation park covering TCM, chemical drugs, and biological drugs to support pharmaceutical technology needs[150]. - The company has a total of 14 ongoing R&D projects, including both innovative and second-development drugs, with various stages of clinical trials[153]. Market Strategy - The company aims to expand its product market share through strategic participation in national centralized procurement, with 14 product specifications selected for 2025, providing more high-quality medication options[79]. - The marketing strategy emphasizes a comprehensive coverage of sales management systems across various medical institutions and retail markets, driving marketing performance[78]. - The company is focusing on the outpatient market as a new growth engine, adapting to policy changes and reshaping its business model to meet diverse market needs[183]. - The company aims to achieve its annual targets by customizing marketing plans for each business unit, focusing on "broad coverage, deep penetration, and precise output" for 2025 core performance indicators[195]. - The company is focusing on a multi-channel marketing strategy, targeting high-quality medical institutions and retail chains[161]. Product Development and Innovation - The company has completed acquisitions of 23 products, including Dan Ning Pian and An Gong Niu Huang Wan, enhancing its product pipeline and clinical competitiveness[56]. - The company is exploring international market opportunities by seeking collaborations on innovative and generic drug projects that align with its strategic development direction[150]. - The company plans to acquire complementary products in major disease treatment areas to inject new growth momentum into its future development[188]. - The company is committed to quality control and safety in drug production, adhering to strict quality standards and regulatory requirements throughout the drug lifecycle[84]. Industry Trends - The pharmaceutical industry saw a 3.4% year-on-year increase in value added for large-scale enterprises, with total revenue for the industry remaining flat at 2.976 trillion yuan[37]. - The traditional Chinese medicine industry is experiencing a profound transformation from scale expansion to quality-driven growth, with the industrial output value accounting for 24.1% of the pharmaceutical industry's revenue in 2023[36]. - The overall pharmaceutical market is expected to grow at a rate of 7%-8%, slightly above China's GDP growth forecast of approximately 5.2%[139]. - The aging population in China is projected to exceed 420 million by 2035, leading to an increased demand for chronic disease management, which presents significant opportunities for traditional Chinese medicine[182]. Awards and Recognition - The company has been recognized with multiple awards, including the "Five-Star Brand" and "Five-Star After-Sales Service" certifications, highlighting its brand and service excellence[49]. - The company has been recognized with multiple awards, including "Most Investment Value Listed Company" and "Corporate Social Responsibility Award" for its brand value[104]. - The company ranked among the top 30 traditional Chinese medicine listed companies in 2024, highlighting its competitive position in the industry[34].

黑龙江珍宝岛药业股份有限公司2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2025 年第一季度报告 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同 | | --- | --- | --- | --- | | | | | 期增减变动幅度(%) | | 营业收入 | 468,943,569.26 | 1,117,297,002.98 | -58.03 | | 归属于上市公司股东的净 | 75,295,443.26 | 293,365,824.9 ...

Core Viewpoint - Zhenbaodao (603567.SH) reported a net profit of 438 million yuan for 2024, with a 20.23% year-on-year growth in pharmaceutical industrial revenue, attributed to enhanced marketing channel reforms and improved product competitiveness [1]. Group 1: Financial Performance - The company achieved a total revenue of 2.704 billion yuan for the year [1]. - The net profit attributable to shareholders reached 438 million yuan [1]. - The pharmaceutical industrial revenue grew by 20.23% compared to the previous year [1]. Group 2: Business Development - The company has made significant progress in its marketing channel reforms, leading to increased market coverage and product competitiveness [1]. - The traditional Chinese medicine sector showed steady progress, with the "Shennongzhou" e-commerce platform complementing offline markets [1]. - New drug research and product sales are advancing smoothly, with clinical trial approvals for innovative traditional Chinese medicine and multiple quality generic drugs [1]. Group 3: Strategic Initiatives - The company has implemented a refined招商模式 (refined recruitment model) to achieve extensive market coverage [1]. - The strategy focuses on driving product volume growth at the terminal level [1].

珍宝岛（603567）公告，2025年第一季度营收为4.69亿元，同比下降58.03%；净利润为7529.54万元， 同比下降74.33%。 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-021 黑龙江珍宝岛药业股份有限公司 关于变更持续督导保荐代表人的公告 发行股票项目持续督导保荐代表人。为保证相关持续督导工作有序开展，国新证 券拟委派乔军文先生接替丁力先生担任本项目持续督导期间的保荐代表人，继续 履行相关职责和义务。本次保荐代表人变更后，公司 2020 年非公开发行股票项 目持续督导保荐代表人为王晓宇先生和乔军文先生。（具体内容详见公司 2024 年 1 月 25 日在上交所网站 www.sse.com.cn 披露的临 2024-003 号公告） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）2020 年非公开发行 A 股股票项目已于 2021 年完成发行工作，国新证券股份有限公司（原华融证券股 份有限公司，以下简称"国新证券"）作为该项目的保荐机构，原指派张韬、乔 绪德担任持续督导的保荐代表人，持续督导期至 2022 年 12 月 31 日。截至本公 告披露日，持续督导期已满，鉴于公司募集资 ...

| 缬沙坦片 | 片剂 | 80mg | 国药准字 | CYHB2500378 | 2025B01098 | 号)"，药品批 | | --- | --- | --- | --- | --- | --- | --- | | | | | H20233694 | | | 准文号不变。 | | 缬沙坦片 | 片剂 | 160mg | 国药准字 | CYHB2500379 | 2025B01100 | 转让药品的生 | | | | | H20233693 | | | 产场地、处方、 | | 盐酸多奈 | 片剂 | 5mg | 国药准字 | CYHB2500370 | 2025B01096 | 生产工艺、质 | | 哌齐片 | | | H20249351 | | | 量标准等与原 | | 盐酸多奈 | | | 国药准字 | | | 药品一致，不 | | | | | | | | 发生变更。转 | | | | | | | | 让的药品在通 | | | | | | | | 过药品生产质 | | | 片剂 | 10mg | | CYHB2500369 | 2025B01103 | 量管理规范符 | | 哌齐片 | | | H20 ...

Core Viewpoint - The announcement indicates that Harbin Zhenbao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhenbao Island (603567), has received approval from the National Medical Products Administration for the transfer of marketing authorization for ten drugs from Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd. to Harbin Zhenbao Pharmaceutical Co., Ltd. This change is not expected to have a significant impact on the company's current operating performance [1]. Group 1 - The approval includes the transfer of marketing authorization for ten drugs, which are Olanzapine Tablets, Apixaban Tablets, Escitalopram Oxalate Tablets, Desloratadine Tablets, Voriconazole Tablets, Mecobalamin Tablets, Rivaroxaban Tablets, Valsartan Tablets, and Donepezil Hydrochloride Tablets [1]. - The change in marketing authorization holders is a strategic move for Harbin Zhenbao Pharmaceutical Co., Ltd. to consolidate its product portfolio [1]. - The company emphasizes that this regulatory approval will not materially affect its current financial performance [1].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-019 黑龙江珍宝岛药业股份有限公司 关于转让全资子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）已 于 2023 年 8 月将全资子公司虎林市方圣医药科技有限公司（以下简称"虎林方 圣"，现已更名为"哈尔滨市方圣医药科技有限公司"）100%股权转让给黑龙江 和晖制药有限公司（以下简称"和晖制药"），交易价格为 4.25 亿元。 ● 本次交易是对公司前期转让虎林方圣 100%股权事项的补充披露。 一、交易概述 （一）本次交易的基本情况 公司之股权转让协议》，拟将虎林方圣 100%股权转让给和晖制药，交易价格为 转让费 4.20 亿元(其中 1.71 亿元公司前期已取得，剩余技术转让费 2.49 亿元)。 股权交易价格较账面价值溢价 318 万元。 （二）本次资产交易的目的和原因 虎林方圣持有黄芪注射液 2ml、血塞通注射液 2ml、舒血宁注射液 10ml、刺 五加注 ...